Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis
Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), there are lack of effective and proven treatments for end-stage renal disease (ESRD). The present study aims to evaluate the effectiveness of regdanvimab on mortality in COVID...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society of Nephrology
2024-01-01
|
| Series: | Kidney Research and Clinical Practice |
| Subjects: | |
| Online Access: | http://krcp-ksn.org/upload/pdf/j-krcp-23-137.pdf |
| _version_ | 1797311459160489984 |
|---|---|
| author | Youn Kyung Kee Hayne Cho Park Su Jin Yoon Sungbong Yu Eunsil Ko AJin Cho Do Hyoung Kim Jinseog Kim Young-Ki Lee |
| author_facet | Youn Kyung Kee Hayne Cho Park Su Jin Yoon Sungbong Yu Eunsil Ko AJin Cho Do Hyoung Kim Jinseog Kim Young-Ki Lee |
| author_sort | Youn Kyung Kee |
| collection | DOAJ |
| description | Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), there are lack of effective and proven treatments for end-stage renal disease (ESRD). The present study aims to evaluate the effectiveness of regdanvimab on mortality in COVID-19–infected patients on hemodialysis (HD). Methods We conducted an observational retrospective study in 230 COVID-19–infected patients on HD, of whom 77 (33.5%) were administered regdanvimab alone or in combination with dexamethasone or remdesivir during hospitalization (regdanvimab group) and 153 patients (66.5%) were not (no regdanvimab group). The primary outcome was in-hospital mortality. We compared mortality rates according to the use of regdanvimab and investigated the factors associated with mortality. Results Fifty-nine deaths occurred during hospitalization, 49 in the no regdanvimab group (32.0%) and 10 in the regdanvimab group (13.0%), and the mortality rate was significantly higher in the no regdanvimab group than that in the regdanvimab group (p = 0.001). Multivariate Cox regression analysis showed that malignancy (p = 0.001), SPO2 of <95% at admission (p = 0.003), and administration of antibiotics and regdanvimab (p = 0.007 and p = 0.002, respectively) were significantly associated factors with mortality. Conclusion Regdanvimab administration is beneficial in improving prognosis in hospitalized COVID-19 patients on HD. Considering the vulnerability to infection and high mortality of ESRD patients, regdanvimab may be considered as a therapeutic option in COVID-19 patients on HD. |
| first_indexed | 2024-03-08T01:59:59Z |
| format | Article |
| id | doaj.art-9c1efee305264f92a8819f46eee7d39d |
| institution | Directory Open Access Journal |
| issn | 2211-9132 2211-9140 |
| language | English |
| last_indexed | 2024-03-08T01:59:59Z |
| publishDate | 2024-01-01 |
| publisher | The Korean Society of Nephrology |
| record_format | Article |
| series | Kidney Research and Clinical Practice |
| spelling | doaj.art-9c1efee305264f92a8819f46eee7d39d2024-02-14T06:28:46ZengThe Korean Society of NephrologyKidney Research and Clinical Practice2211-91322211-91402024-01-0143111112110.23876/j.krcp.23.1376311Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysisYoun Kyung Kee0Hayne Cho Park1Su Jin Yoon2Sungbong Yu3Eunsil Ko4AJin Cho5Do Hyoung Kim6Jinseog Kim7Young-Ki Lee8 Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Republic of Korea Hallym Kidney Research Institute, Hallym University College of Medicine, Seoul, Republic of Korea Department of Internal Medicine, Good Samaritan Bagae Hospital, Pyeongtaek, Republic of Korea Department of General Surgery, Good Samaritan Bagae Hospital, Pyeongtaek, Republic of Korea National Emergency Medical Center, National Medical Center, Seoul, Republic of Korea Hallym Kidney Research Institute, Hallym University College of Medicine, Seoul, Republic of Korea Hallym Kidney Research Institute, Hallym University College of Medicine, Seoul, Republic of Korea Department of Bigdata and Applied Statistics, Dongguk University, Gyeongju, Republic of Korea Hallym Kidney Research Institute, Hallym University College of Medicine, Seoul, Republic of KoreaBackground Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), there are lack of effective and proven treatments for end-stage renal disease (ESRD). The present study aims to evaluate the effectiveness of regdanvimab on mortality in COVID-19–infected patients on hemodialysis (HD). Methods We conducted an observational retrospective study in 230 COVID-19–infected patients on HD, of whom 77 (33.5%) were administered regdanvimab alone or in combination with dexamethasone or remdesivir during hospitalization (regdanvimab group) and 153 patients (66.5%) were not (no regdanvimab group). The primary outcome was in-hospital mortality. We compared mortality rates according to the use of regdanvimab and investigated the factors associated with mortality. Results Fifty-nine deaths occurred during hospitalization, 49 in the no regdanvimab group (32.0%) and 10 in the regdanvimab group (13.0%), and the mortality rate was significantly higher in the no regdanvimab group than that in the regdanvimab group (p = 0.001). Multivariate Cox regression analysis showed that malignancy (p = 0.001), SPO2 of <95% at admission (p = 0.003), and administration of antibiotics and regdanvimab (p = 0.007 and p = 0.002, respectively) were significantly associated factors with mortality. Conclusion Regdanvimab administration is beneficial in improving prognosis in hospitalized COVID-19 patients on HD. Considering the vulnerability to infection and high mortality of ESRD patients, regdanvimab may be considered as a therapeutic option in COVID-19 patients on HD.http://krcp-ksn.org/upload/pdf/j-krcp-23-137.pdfcovid-19renal dialysismortalityregdanvimab |
| spellingShingle | Youn Kyung Kee Hayne Cho Park Su Jin Yoon Sungbong Yu Eunsil Ko AJin Cho Do Hyoung Kim Jinseog Kim Young-Ki Lee Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis Kidney Research and Clinical Practice covid-19 renal dialysis mortality regdanvimab |
| title | Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis |
| title_full | Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis |
| title_fullStr | Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis |
| title_full_unstemmed | Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis |
| title_short | Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis |
| title_sort | effectiveness of regdanvimab on mortality in covid 19 infected patients on hemodialysis |
| topic | covid-19 renal dialysis mortality regdanvimab |
| url | http://krcp-ksn.org/upload/pdf/j-krcp-23-137.pdf |
| work_keys_str_mv | AT younkyungkee effectivenessofregdanvimabonmortalityincovid19infectedpatientsonhemodialysis AT haynechopark effectivenessofregdanvimabonmortalityincovid19infectedpatientsonhemodialysis AT sujinyoon effectivenessofregdanvimabonmortalityincovid19infectedpatientsonhemodialysis AT sungbongyu effectivenessofregdanvimabonmortalityincovid19infectedpatientsonhemodialysis AT eunsilko effectivenessofregdanvimabonmortalityincovid19infectedpatientsonhemodialysis AT ajincho effectivenessofregdanvimabonmortalityincovid19infectedpatientsonhemodialysis AT dohyoungkim effectivenessofregdanvimabonmortalityincovid19infectedpatientsonhemodialysis AT jinseogkim effectivenessofregdanvimabonmortalityincovid19infectedpatientsonhemodialysis AT youngkilee effectivenessofregdanvimabonmortalityincovid19infectedpatientsonhemodialysis |